{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:56:27Z","timestamp":1793393787886,"version":"4.5.0"},"reference-count":52,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100001146","name":"Greenwall Foundation","doi-asserted-by":"publisher","award":["no award\/grant number"],"award-info":[{"award-number":["no award\/grant number"]}],"id":[{"id":"10.13039\/100001146","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2025,8,25]]},"abstract":"<jats:p>Patient organisations aim to advance the interests of patient populations living with various diseases, disabilities and health conditions. However, because the members of a given patient population often have varied or even conflicting interests, the way in which a patient organisation pursues its mission can be contentious, as it typically involves prioritising the interests of some patients over others. There is some evidence to suggest that in recent years, patient organisations have increasingly directed resources toward supporting research, a trend that may be spurred by the rise of venture philanthropy\u2014an emerging model in which patient organisations make high-risk, high-reward research investments with the goal of advancing treatments and cures. While venture philanthropy has garnered significant support, it has also faced criticism from patients currently living with serious illnesses, who argue that research investments benefit future patients at the expense of services for current patients. Against the backdrop of these developments, this paper investigates the ethics of patient organisations pursuing cures over care. I begin by identifying a key assumption shared by proponents and critics of venture philanthropy, which suggests that patient organisations can permissibly choose whether they aim to benefit current or future patients. Yet I go on to argue that even if patient organisations may permissibly prioritise future patients, their promissory, stewardship and representative obligations may, under some circumstances, limit their discretion to invest in research. Under other circumstances, however, these same obligations may give patient organisations reasons to prioritise research.<\/jats:p>","DOI":"10.1136\/jme-2025-110875","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:20:34Z","timestamp":1758043234000},"page":"jme-2025-110875","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Patient organisations, venture philanthropy and the ethics of pursuing cures over care"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5273-3877","authenticated-orcid":false,"given":"Matthew S","family":"McCoy","sequence":"first","affiliation":[{"name":"Department of Medical Ethics and Health Policy, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"2025091610202342000_jme-2025-110875v1.1","unstructured":"Harris G . Medical charities once advised on coping with a disease. Now they try to cure it. The New York Times. 2016 Available: https:\/\/www.nytimes.com\/2016\/11\/06\/giving\/medical-charities-once-advised-on-coping-with-a-disease-now-they-try-to-cure-it.html"},{"key":"2025091610202342000_jme-2025-110875v1.2","doi-asserted-by":"crossref","unstructured":"Readel AM . Finding a Cure: Incentivizing Partnerships Between Disease Advocacy Groups and Academic and Commercial Researchers. SSRN Journal 2013;26. doi:10.2139\/ssrn.2349415","DOI":"10.2139\/ssrn.2349415"},{"key":"2025091610202342000_jme-2025-110875v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/gim.0b013e3182310ba0"},{"key":"2025091610202342000_jme-2025-110875v1.4","unstructured":"Giusti K , Hamermesh RG . How nonprofit foundations can sustainably fund disease research. Harvard Business Review; 2020. Available: https:\/\/hbr.org\/2020\/09\/how-nonprofit-foundations-can-sustainably-fund-disease-research"},{"key":"2025091610202342000_jme-2025-110875v1.5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMra1612575","article-title":"Academic, Foundation, and Industry Collaboration in Finding New Therapies","volume":"376","author":"Ramsey","year":"2017","journal-title":"N Engl J Med"},{"key":"2025091610202342000_jme-2025-110875v1.6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/d41573-019-00129-1","article-title":"Harnessing venture philanthropy to accelerate medical progress","volume":"18","author":"L\u00f3pez","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2025091610202342000_jme-2025-110875v1.7","unstructured":"Milken Institute . The research acceleration and innovation network (train). 2025. Available: https:\/\/milkeninstitute.org\/health\/fastercures\/engaging-patients-research-and-health\/research-acceleration-and-innovation-network-train"},{"key":"2025091610202342000_jme-2025-110875v1.8","unstructured":"Goldberg M . Patient advocacy groups and innovators must partner to advance new treatments. STAT; 2021. Available: https:\/\/www.statnews.com\/2021\/07\/06\/patient-advocacy-groups-and-innovators-must-partner-to-advance-new-treatments\/"},{"key":"2025091610202342000_jme-2025-110875v1.9","doi-asserted-by":"crossref","unstructured":"Best RK . Common enemies: Disease campaigns in America. Oxford, New York: Oxford University Press, 2019:272.","DOI":"10.1093\/oso\/9780190918408.001.0001"},{"key":"2025091610202342000_jme-2025-110875v1.10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.neuron.2014.10.030","article-title":"Transforming our approach to translational neuroscience: the role and impact of charitable nonprofits in research","volume":"84","author":"Joyce","year":"2014","journal-title":"Neuron"},{"key":"2025091610202342000_jme-2025-110875v1.11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/1467-9566.00174","article-title":"Waiting for the cure: mapping the social relations of human gene therapy research","volume":"21","author":"Stockdale","year":"1999","journal-title":"Sociology Health & Illness"},{"key":"2025091610202342000_jme-2025-110875v1.12","unstructured":"Graham J . Leading Alzheimer\u2019s group splinters over claims of misplaced priorities and lavish spending. STAT; 2016. Available: https:\/\/www.statnews.com\/2016\/03\/02\/alzheimers-association-split\/"},{"key":"2025091610202342000_jme-2025-110875v1.13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/JND-180330","article-title":"Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy","volume":"6","author":"Pacione","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"2025091610202342000_jme-2025-110875v1.14","unstructured":"Lewis-Kraus G . When dying patients want unproven drugs. The New Yorker; 2023. Available: https:\/\/www.newyorker.com\/magazine\/2023\/06\/26\/relyvrio-als-fda-approval"},{"key":"2025091610202342000_jme-2025-110875v1.15","unstructured":"Court E E . ALS patient group unhappy with how $115 million raised by the ice bucket challenge is being spent. MarketWatch; 2024. Available: https:\/\/www.marketwatch.com\/story\/als-patients-are-unhappy-with-how-115-million-raised-by-the-ice-bucket-challenge-is-being-spent-2018-02-14"},{"key":"2025091610202342000_jme-2025-110875v1.16","unstructured":"Aitken M , Nass D , Kern J . Supporting patients through research collaboration. The IQVIA Institute for Human Data Science; 2024. Available: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/supporting-patients-through-research-collaboration"},{"key":"2025091610202342000_jme-2025-110875v1.17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10961-013-9311-1","article-title":"Accelerating commercialization: a new model of strategic foundation funding","volume":"39","author":"Feldman","year":"2014","journal-title":"J Technol Transf"},{"key":"2025091610202342000_jme-2025-110875v1.18","doi-asserted-by":"crossref","unstructured":"Lechterman TM . The tyranny of generosity: Why philanthropy corrupts our politics and how we can fix it. New York, NY, United States of America: Oxford University Press, 2021:280.","DOI":"10.1093\/oso\/9780197611418.001.0001"},{"key":"2025091610202342000_jme-2025-110875v1.19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/jamainternmed.2016.8443","article-title":"Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest","volume":"177","author":"Rose","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2025091610202342000_jme-2025-110875v1.20","unstructured":"TRAIN . What is venture philanthropy. 2023. Available: https:\/\/web.archive.org\/web\/20230330151520\/https:\/\/train.fastercures.org\/about\/what-is-venture-philanthropy\/"},{"key":"2025091610202342000_jme-2025-110875v1.21","unstructured":"Pollack A . Deal by cystic fibrosis foundation raises cash and some concern. The New York Times; 2014. Available: https:\/\/www.nytimes.com\/2014\/11\/19\/business\/for-cystic-fibrosis-foundation-venture-yields-windfall-in-hope-and-cash.html"},{"key":"2025091610202342000_jme-2025-110875v1.22","unstructured":"Bilodeau K . Nonprofits are bridging r&d\u2019s valley of death. PharmaVoice; 2023. Available: https:\/\/www.pharmavoice.com\/news\/nonprofits-research-dev-valley-of-death-Advancium\/639553\/"},{"key":"2025091610202342000_jme-2025-110875v1.23","unstructured":"Giusti K , Hamermesh RG . Venture models can accelerate cures but aren\u2019t for the faint of heart. Harvard Business School Kraft Precision Medicine Accelerator; 2021. Available: https:\/\/www.hbs.edu\/kraft-accelerator\/assets\/pdf\/unique_venture_models_2021.pdf"},{"key":"2025091610202342000_jme-2025-110875v1.24","doi-asserted-by":"crossref","first-page":"W5","DOI":"10.1080\/15265161.2018.1536769","article-title":"Response to Open Peer Commentaries on \u201cHealth Research Priority Setting: The Duties of Individual Funders\u201d","volume":"19","author":"Millum","year":"2019","journal-title":"Am J Bioeth"},{"key":"2025091610202342000_jme-2025-110875v1.25","doi-asserted-by":"crossref","unstructured":"Pummer T . The rules of rescue: Cost, distance, and effective altruism. Oxford, New York: Oxford University Press, 2022:264.","DOI":"10.1093\/oso\/9780190884147.001.0001"},{"key":"2025091610202342000_jme-2025-110875v1.26","doi-asserted-by":"crossref","unstructured":"Cordelli C . The Privatized State. Princeton Oxford: Princeton University Press, 2020:356.","DOI":"10.23943\/princeton\/9780691205755.001.0001"},{"key":"2025091610202342000_jme-2025-110875v1.27","unstructured":"Team gleason foundation - guidestar profile. 2025 Available: https:\/\/www.guidestar.org\/profile\/45-3689316"},{"key":"2025091610202342000_jme-2025-110875v1.28","unstructured":"ALS association - guidestar profile. 2025. Available: https:\/\/www.guidestar.org\/profile\/20-1742120"},{"key":"2025091610202342000_jme-2025-110875v1.29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/15265161.2018.1523490","article-title":"Health Research Priority Setting: The Duties of Individual Funders","volume":"18","author":"Pierson","year":"2018","journal-title":"Am J Bioeth"},{"key":"2025091610202342000_jme-2025-110875v1.30","unstructured":"Do what\u2019s right - als ice bucket challenge edition. ALS Advocacy; 2014. Available: http:\/\/als-advocacy.blogspot.com\/2014\/08\/do-whats-right-als-ice-bucket-challenge.html"},{"key":"2025091610202342000_jme-2025-110875v1.31","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1161\/CIRCULATIONAHA.121.057617","article-title":"American Heart Association\u2019s 2024 Impact Goal: Every Person Deserves the Opportunity for a Full, Healthy Life","volume":"144","author":"Lloyd-Jones","year":"2021","journal-title":"Circulation"},{"key":"2025091610202342000_jme-2025-110875v1.32","unstructured":"Allergy & asthma day capitol hill 2024: advocating for health equity. Allergy & Asthma Network; 2025. Available: https:\/\/allergyasthmanetwork.org\/news\/allergy-asthma-advocacy-aadch-2024\/"},{"key":"2025091610202342000_jme-2025-110875v1.33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bioe.13284","article-title":"Accounting for future populations in health research","volume":"38","author":"Pierson","year":"2024","journal-title":"Bioethics"},{"key":"2025091610202342000_jme-2025-110875v1.34","doi-asserted-by":"crossref","unstructured":"Dresser R . When science offers salvation: Patient advocacy and research ethics. Oxford University Press, 2001:240.","DOI":"10.1093\/oso\/9780195143133.001.0001"},{"key":"2025091610202342000_jme-2025-110875v1.35","unstructured":"Florko N . With its aduhelm proposal, medicare is stepping into a heated debate about how best to improve equity in alzheimer\u2019s treatment. STAT; 2022. Available: https:\/\/www.statnews.com\/2022\/01\/13\/medicare-aduhelm-proposal-debate-equity-alzheimers-treatment\/"},{"key":"2025091610202342000_jme-2025-110875v1.36","doi-asserted-by":"crossref","unstructured":"Knight TG , Deal AM , Dusetzina SB , et al . Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. J Oncol Pract 2018;JOP1800120. doi:10.1200\/JOP.18.00120","DOI":"10.1200\/JOP.18.00120"},{"key":"2025091610202342000_jme-2025-110875v1.37","doi-asserted-by":"crossref","first-page":"104032","DOI":"10.1016\/j.respol.2020.104032","article-title":"Getting ahead in the race for a cure: How nonprofits are financing biomedical R&D","volume":"49","author":"Graddy-Reed","year":"2020","journal-title":"Res Policy"},{"key":"2025091610202342000_jme-2025-110875v1.38","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/S2214-109X(23)00055-4","article-title":"When should global health actors prioritise more uncertain interventions?","volume":"11","author":"Pierson","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2025091610202342000_jme-2025-110875v1.39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1057\/s41292-017-0061-4","article-title":"Chasing cures: Rewards and risks for rare disease patient organisations involved in research","volume":"13","author":"Pinto","year":"2018","journal-title":"Biosocieties"},{"key":"2025091610202342000_jme-2025-110875v1.40","unstructured":"Lendner P . Venture philanthropy straddles two worlds. Managed Care Magazine. 2017 Available: https:\/\/www.managedcaremag.com\/archives\/2017\/6\/venture-philanthropy-straddles-two-worlds"},{"key":"2025091610202342000_jme-2025-110875v1.41","unstructured":"Whitlock J . Parents are becoming drug developers to find a cure for their children\u2019s rare diseases. Fortune, 2022. Available: https:\/\/fortune.com\/2022\/07\/21\/parents-drug-developers-children-rare-disease-treatment\/"},{"key":"2025091610202342000_jme-2025-110875v1.42","unstructured":"Duchenne muscular dystrophy. Genetic and rare diseases information center; 2024. Available: https:\/\/rarediseases.info.nih.gov\/diseases\/6291\/duchenne-muscular-dystrophy"},{"key":"2025091610202342000_jme-2025-110875v1.43","unstructured":"American diabetes association. American Diabetes Association: Our Vision and Mission; 2025. Available: https:\/\/diabetes.org\/about-us"},{"key":"2025091610202342000_jme-2025-110875v1.44","unstructured":"Alzheimer\u2019s Association . Our impact | Alzheimer\u2019s association. 2025. Available: https:\/\/www.alz.org\/about\/our-impact"},{"key":"2025091610202342000_jme-2025-110875v1.45","unstructured":"National Multiple Sclerosis Society . Empowering people affected by ms to live their best lives. 2025. Available: https:\/\/www.nationalmssociety.org"},{"key":"2025091610202342000_jme-2025-110875v1.46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/jopp.12137","article-title":"On Representing","volume":"26","author":"Rehfeld","year":"2018","journal-title":"J Political Philosophy"},{"key":"2025091610202342000_jme-2025-110875v1.47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/15265161.2020.1730482","article-title":"Ethical Advocacy Across the Autism Spectrum: Beyond Partial Representation","volume":"20","author":"McCoy","year":"2020","journal-title":"Am J Bioeth"},{"key":"2025091610202342000_jme-2025-110875v1.48","doi-asserted-by":"crossref","unstructured":"Montanaro L . Who Elected Oxfam?: A democratic defense of self-appointed representatives. Cambridge: Cambridge University Press, 2017.","DOI":"10.1017\/9781108297721"},{"key":"2025091610202342000_jme-2025-110875v1.49","unstructured":"Empowering patient-driven research to improve patient outcomes. IQVIA; 2022. Available: https:\/\/www.iqvia.com\/library\/white-papers\/empowering-patient-driven-research-to-improve-patient-outcomes"},{"key":"2025091610202342000_jme-2025-110875v1.50","unstructured":"Madelung M , Johnson S , Weiss A . Making best bets: prioritizing expenditure for maximizing impact on patient communities. IQVIA; 2023. Available: https:\/\/www.iqvia.com\/locations\/united-states\/library\/white-papers\/making-best-bets-prioritizing--expenditure-for-maximizing-impact-on--patient-communities"},{"key":"2025091610202342000_jme-2025-110875v1.51","unstructured":"Rubin E . Tend the wound or find the cure? some question use of ice-bucket millions. Non Profit News | Nonprofit Quarterly; 2018. Available: https:\/\/nonprofitquarterly.org\/tend-wound-find-cure-question-use-ice-bucket-millions\/"},{"key":"2025091610202342000_jme-2025-110875v1.52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2308\/TAR-2019-0497","article-title":"Managing Large Donor Influence","volume":"98","author":"Carniol","year":"2023","journal-title":"The Accounting Review"}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jme-2025-110875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:20:42Z","timestamp":1758043242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/jme-2025-110875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":52,"alternative-id":["10.1136\/jme-2025-110875"],"URL":"https:\/\/doi.org\/10.1136\/jme-2025-110875","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}